Wednesday, 22 Jan 2020

PsA/SpA

Datesort ascending Type Title Save
08 Jan 2020 Social Systematic literature of biologic Rx of dactylitis & enthesitis in Psoriatic arthritis. 18 trials, 6981 patients showed that TNF inhib & ustekinumab, secukinumab, ixekizumab were 2-3 fold significantly better than PBO at resolution of dactylitis by Wk 24. https://t.co/HlQcw5cXsN
06 Jan 2020 News Taltz Shines in Non-Radiographic Axial Spondyloarthritis
27 Dec 2019 News Best of 2019 - SEAM-PsA Study - Does Monotherapy MTX Win Despite Losing to Etanercept in Psoriatic Arthritis?
26 Dec 2019 News Best of 2019 - ACR/SPARTAN Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
20 Dec 2019 Social COAST-X trial: Ixekizumab was superior to placebo for improving signs and symptoms in patients with non-radiographic axial spondyloarthritis at weeks 16 and 52. ASAS40 at week 52 IXE q4W 30% vs. IXE Q2W 31% vs PBO 13%, p=0·0037 https://t.co/GrQnakvor1
20 Dec 2019 News Upadacitinib Effective in Ankylosing Spondylitis
17 Dec 2019 Social Should AS/SpA pts have ECHO for AI/AR? I say YES; Swedish study of 6448 AS pts shows 2 fold higher risk AI https://t.co/lchlsGXAJi. Another ECHO study 187 AS pts shows an incr prevalence (18%) of AI murmur esp w/ longstanding disease or age >50 (>50%) https://t.co/Np21FwCbBP
10 Dec 2019 Social Comparison of radiographic (r-axSpA) & non-radiographic axSpA (nr-axSpA) pts from the DESIR study shows a higher prevalence of males in r-axSpA, but no significant differences in peripheral arthritis, extra-rheumatic Sxs, PROs, Sick leave between groups https://t.co/nIndsJuFCN
05 Dec 2019 News Secukinumab Improves Enthesitis
03 Dec 2019 Social RT @RWCSmtg: Filgotinib in AS #rheumatology https://t.co/vTsPjoogHv
03 Dec 2019 Social Spinal/SI MRI in the gen. population finds a high frequency of inflammatory and fatty MRI lesions suggestive of axSpA. MRI done in 793 volunteers < 45 yrs (49% males, 8.4% B27+). SI tJ Bone marrow edema in 17%, Vertebra BME 27% & fatty lesions in 81% https://t.co/XOzyWCyLyC
03 Dec 2019 News Spondyloarthritis Affects Pregnancy Outcomes
30 Nov 2019 Social Guselkumab, anti-IL23 in PsA Ph3 DISCOVER-1 trial in bio-naive or 30% prior TNFi = Effective at Wk 24 Safety same as with psoriasis trials. No Tb signal, No IBD signal. #ACR19 Abst0807 @_connectedcare https://t.co/d7hrn8VQO8
29 Nov 2019 Social Phase 2b Bimekizumab study results in PsA shows neutralizing IL 17F and IL 17A may be a new target for LDA/treatment. https://t.co/45Vahy36g7 #ACR19 @uptoTate abs#2881
29 Nov 2019 Social RT @JointMD: Panel Presentation: What’s New in Psoriatic Arthritis. So honored to join my colleagues Alexis Ogdie, Jose Scher, and Jessie W…
27 Nov 2019 Social #ACR19 ABST #1590 -3 RCTs show anti-TNFα & IL-12/23 associated w/significant improvement in depressive symptoms in PSA. GO-REVEAL depression ⬇️ 31.2 to 19.5% w/golimumab; PSUMIT1 36.2 to 20.3% & PSUMIT2 37.2 to 21.2% ⬇️ w/UST. minimal change w/PBO in all 3 trials @DrPetryna
27 Nov 2019 News IL-17 Inhibitors In Non-Radiographic Axial SpA
26 Nov 2019 Social #ACR19 ABST #1513 Tofacitinib efficacy in PSA ⬇️ if BL BMI ≥ 35 . Safety consistent across all BL BMI categories. 3 CV events: non-fatal cerebrovascular accident, TIA(both Tofa 5 mg BID, BMI ≥ 30 – < 35), and artery revascularization in PBO; BMI ≥ 35 https://t.co/S1WQDRFqTv https://t.co/oEKTnwUvJP
26 Nov 2019 Social #ACR19 abst #2476 Retrospective 2000-18 cohort study on side effects of MTX &TNFi in PSA vs RA: more side effects reported in MTX-PSA (42-46%) compared to MTX-RA pts (26-30%) or PsA or RA pts initiating a TNFi (20-25% of RA and 22-27% of PsA) @DrPetryna https://t.co/Eo3zwDgJMr https://t.co/eaq1gfD1eX
26 Nov 2019 Social #ACR19 ABS# 1481 Corrona PsA/SpA Registy: real-world use of COMBINATION Apremilast + biologics happens mostly in pts who received prior biologic therapy & pts not able to achieve MDA. @DrPetryna https://t.co/7OdLBalnPZ